Reduction of Falls in the Elderly - Parkinson's Disease (REFINE-PD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The REFINE-PD study is a controlled trial embedded within a larger cluster controlled study (the IMPACT study). The study aims to investigate the efficacy of a multifactorial falls prevention program for patients with Parkinson's Disease (PD). This program contains PD-specific elements (e.g., optimizing dopaminergic therapy), plus a generic falls prevention program. The intervention will be tailored to each individual's specific risk profile for falls, as identified during detailed baseline examination.
| Condition | Intervention | Phase |
|---|---|---|
|
Parkinson's Disease |
Other: Multifactorial fall prevention program Other: Usual care |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Reduction of Falls in the Elderly - Parkinson's Disease |
- Incidence of falls [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Number of fallers (secondary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Falls Efficacy Scale (tertiary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Unified Parkinson's Disease rating scale (UPDRS) Motor Examination (part III) (tertiary) [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Parkinson's Disease quality of life questionnaire (PDQL) (tertiary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Self-assessment Parkinson's Disease disability scale (SPDDS)(tertiary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Caregiver burden assessed with BELA-A-k, SF-36, and HADS (tertiary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Number of injurious falls (secondary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Number of patients with injurious falls (secondary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Freezing of gait (tertiary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Costs (secondary) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
| Enrollment: | 187 |
| Study Start Date: | August 2007 |
| Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: I
Multifactorial fall prevention program
|
Other: Multifactorial fall prevention program
Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
|
|
II
Usual care
|
Other: Usual care
Usual care
|
Detailed Description:
Falls and postural instability are common complications of advanced Parkinson's Disease (PD). Falls in PD often have devastating consequences, leading to a poor overall prognosis. In addition, falls in PD are associated with substantial medical expenses due to treatment of injuries and nursing home admission. The risk of falls in older PD patients is aggravated by "generic" age-related factors, such as sedative medication or poor vision. Observations on elderly persons without PD suggest that a multifactorial prevention program might be more effective. We propose to investigate the effectiveness of a multifactorial prevention program aimed at the prevention of falls in PD, which is based on disease-specific treatment strategies with demonstrated efficacy in PD, as well as prevention strategies with proven effectiveness for the general elderly population.
In this study an individualised multifactorial program aimed at the prevention of falls in PD containing PD-specific elements and a generic falls prevention program will be compared to usual care.
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with idiopathic Parkinson's Disease, diagnosed according to the Brain Bank criteria of the UK Parkinson's Society
- Regular control by the neurologist
- Living independently in the community
- Able to complete the trial questionnaires
An increased risk for falling, defined as:
- at least one fall in the preceding 12 months OR
- recurrent (monthly) near falls in the preceding 12 months OR
- fear of falling OR (iv) avoidance of activities due to fear of falling OR a combination of these findings
Exclusion Criteria:
- Atypical parkinsonian syndromes
- Hoehn and Yahr stage 5
- Severe cognitive impairment (MMSE < 24)
- Severe co-morbidity (e.g., cancer)
- Planned surgical procedure for PD within the intervention period
- Patients who have already visited the Multidisciplinary Assessment Center
Contacts and Locations| Netherlands | |
| Ziekenhuis Groep Twente, Twenteborg Ziekenhuis | |
| Almelo, Netherlands | |
| Ziekenhuis Rijnstate | |
| Arnhem, Netherlands | |
| Wilhelmina Ziekenhuis Assen | |
| Assen, Netherlands | |
| Ziekenhuis Groep Twente, Streekziekenhuis Midden-Twente | |
| Hengelo, Netherlands | |
| Medisch Centrum Leeuwarden | |
| Leeuwarden, Netherlands | |
| Canisius Wilhelmina Ziekenhuis | |
| Nijmegen, Netherlands | |
| Principal Investigator: | Marten Munneke, PhD | UMC St. Radboud |
| Principal Investigator: | Bastiaan R. Bloem, MD, PhD | UMC St. Radboud |
| Principal Investigator: | Marjolein A. van der Marck, MSc | UMC St. Radboud |
More Information
No publications provided
| Responsible Party: | Dr. M. Munneke, UMC St Radboud, Neurology |
| ClinicalTrials.gov Identifier: | NCT00518648 History of Changes |
| Other Study ID Numbers: | 2007_RP1.1 |
| Study First Received: | August 20, 2007 |
| Last Updated: | November 22, 2010 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Radboud University:
|
Accidental falls Prevention Treatment effectiveness |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on June 17, 2013